Perspective of obesity pharmacotherapy
Authors:
Štěpán Svačina; Petr Sucharda; Zuzana Stránská; Martin Matoulek
Authors‘ workplace:
III. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2014; 153: 127-130
Category:
Review Article
*Článek je věnován k 90. narozeninám prof. MUDr. Vratislava Schreibera, DrSc.
Overview
Obesity is a very common disease with very difficult treatment. Most patients are not able to change their behaviour. Most hopeful for the future is a safe pharmacotherapy which could be widely used. In this review, old and potentially new drugs decreasing weight are mentioned (centrally acting anorectics, orlistat, incretine analogues and gliphlozines). Review of newly in U.S.A used antiobesitics is also mentioned. Finally potentially new principles of obesity pharmacotherapy are enumerated.
Keywords:
obesity – pharmacotherapy – anorectics – principles of action – biological therapy
Sources
1. Schreiber V. Endokrinologie 1989–1990. Čas. Lék. čes. 1991; 130(14): 418–420.
2. Schreiber V. Endokrinologie 1995–1996. Čas. Lék. čes. 1997; 136(8): 240–241.
3. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460(7255): 587–591.
4. Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 2014; 6(5): 836–843.
5. Svačina Š. Obezitologie a teorie metabolického syndromu. Praha: Triton 2013.
6. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363(10): 905–917.
7. Smith SR, Weissman NJ, Anderson CM, et al. Multiticenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363(3): 245–256.
8. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9653): 1906–1913.
9. Steelman GM, Westman EC (eds.) Obesity. Evaluation and Treatment Essentials. New York, London. Informa Helthcare 2010.
10. Gras J. Cetilistat for the treatment of obesity. Drugs Today (Barc) 2013; 49(12): 755–759.
11. Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M. Peripheral targets in obesity treatment: a comprehensive update. Obes Rev 2014; Article first published online
12. Haluzík M, Svačina Š. Inkretinová léčba diabetu. Praha: Mladá fronta 2012.
13. Ferrannini E, Muscelli E, Frascerra S, Baldi S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.J Clin Invest 2014; 124(2): 499–508.
14. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12(8): 1197–1211.
15. Larsen CM, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356(15): 1517–1526.
16. Wu AL, Kolumam G, Stawicki, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med 2011; 3(113): 113.
17. Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes 2014; 7: 73–84.
18. Fried M, et al. Bariatrická a metabolická chirurgie. Praha: Mladá Fronta 2011.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Resisance to thyroid hormones
- Good death: Euthanasia in the eyes of medical students
- Contemporary options and perspectives in the treatment of acromegaly
- Contemporary possibilities of non-oral estrogen-progestin contraception